BioPorto platform validated on Qiagen’s lateral flow system

By Joseph James Whitworth

- Last updated on GMT


Related tags Lateral flow Elisa

BioPorto Diagnostics and Qiagen have validated BioPorto’s generic Rapid Assay Device (gRAD) lateral flow platform on Qiagen’s ESEQuant LR3 Lateral Flow System.

The firms said combining gRAD with the ESEQuant LRS system provides a toolbox for development of lateral flow-based assays which are used in food industry and environmental testing.

They added demand for new applications in the lateral flow market space is rapidly increasing.

No specific antibodies are immobilized on the strip as part of gRAD, making testing a variety of biomarkers and labeling systems more flexible.

The generic lateral flow strip has a test line where a biotinylated capture antibody (or other biotinylated proteins) will bind and a control line.

A range of strips with fluorescence or colorimetric labels or different number of strips and lines can be analysed by the ESEQuant LR3 Lateral Flow System. 

Jan Kuhlmann Andersen, COO of BioPorto, said the combination means it has an assay development process in place to test across a variety of business segments.

With the gRAD platform BioPorto Diagnostics has the ability to offer assay developers across several industries contract development of their assay development.”

Related topics Food safety & quality

Related news

Show more

Follow us


View more